AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller Humira, ...

I rate AbbVie stock as a Strong Buy, based on its FDA approval of Rinvoq. Read the latest analysis on the stock here.

New treatment approved for bipolar I disorder; Rinvoq IBD indications updated; blood-based test for early detection of amyloid pathology; and an oral ...

The Food and Drug Administration (FDA) has approved updated indications for Rinvoq® (upadacitinib) in the treatment of adults with moderately to severely active ulcerative colitis (UC) or Crohn ...

Raymond James analyst Gary Nachman raised the firm’s price target on AbbVie (ABBV) to $250 from $236 and keeps an Outperform rating on the shares.

At 24/7 Wall St., we have closely followed dividend-paying stocks for over 15 years. With a growing audience of savvy Baby ...

Leerink Partners analyst Jeffrey La Rosa maintained a Buy rating on AbbVie on October 14 and set a price target of $243.00. The company’s shares closed yesterday at $226.22. Take advantage of TipRanks ...

The cold and flu brand generated an impressions SOV of 4.71% and 2.9 billion impressions, primarily through CBS and its show GMA 3: What You Need to Know. The Proctor and Gamble brand invested $10.3 ...

Get AbbVie (ABBV) stock updates, legal news, analyst ratings, and growth outlook. Discover why experts are bullish despite ...

Veradermics locked in a new layer of funding with a $150 million series C financing round that will support its ambitions of ...

For investors seeking passive income, probably the most important thing to know about Abbott is that it's a member of the ...

The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called ...